Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: Initial results

Chien-Kuo Wang, Chun Wei Li, Tsyh Jyi Hsieh, Sang Hsiung Chien, Gin Chung Liu, Kun Bow Tsai

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

PURPOSE: To determine if in vivo detection of choline by using hydrogen 1 (1H) magnetic resonance (MR) spectroscopy with dynamic contrast material-enhanced MR imaging can help differentiate between benign and malignant musculoskeletal tumors. MATERIALS AND METHODS: MR imaging was performed in 36 consecutive patients with bone and soft-tissue tumors larger than 1.5 cm in diameter. Examinations were performed at 1.5 T with a surface coil appropriate for the location of the lesions. Single-voxel 1H MR spectroscopy was performed by using a point-resolved spectroscopic sequence with echo times of 40, 135, and 270 msec. The volume of interest within lesions was positioned on the areas of early enhancement (<8 seconds after arterial enhancement) according to the findings of dynamic contrast-enhanced MR imaging with subtraction. The criterion for determining whether choline was present in a lesion was a clearly identifiable peak at 3.2 ppm in at least two of the three spectra acquired at echo times. MR spectroscopic results and histopathologic findings were determined in blinded fashion and compared with κ statistics. P < .001 was considered to indicate a significant difference. RESULTS: Choline was detected in 18 of 19 patients with malignant tumors and in three of 17 patients with benign lesions. The three benign lesions included one perineurioma, one giant cell tumor, and one abscess. Choline was not detected in 14 patients with benign lesions nor in one patient with a densely ossifying low-grade parosteal osteosarcoma. In vivo 1H MR spectroscopy characterized bone and soft-tissue tumors, resulting in a sensitivity of 95%, specificity of 82%, and accuracy of 89% (P < .001). CONCLUSION: Choline can be reliably detected in large malignant bone and soft-tissue tumors by using a multiecho point-resolved spectroscopic protocol. 1H MR spectroscopy can help differentiate malignant from benign musculoskeletal tumors by revealing the presence or absence of water-soluble choline metabolites.

Original languageEnglish
Pages (from-to)599-605
Number of pages7
JournalRadiology
Volume232
Issue number2
DOIs
Publication statusPublished - 2004 Aug 1

Fingerprint

Choline
Magnetic Resonance Spectroscopy
Bone and Bones
Neoplasms
Magnetic Resonance Imaging
Nerve Sheath Neoplasms
Giant Cell Tumors
Osteosarcoma
Abscess
Contrast Media
Hydrogen
Sensitivity and Specificity
Water

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Wang, Chien-Kuo ; Li, Chun Wei ; Hsieh, Tsyh Jyi ; Chien, Sang Hsiung ; Liu, Gin Chung ; Tsai, Kun Bow. / Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy : Initial results. In: Radiology. 2004 ; Vol. 232, No. 2. pp. 599-605.
@article{6883f493dad045bd9cb8fe57adb5936e,
title = "Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: Initial results",
abstract = "PURPOSE: To determine if in vivo detection of choline by using hydrogen 1 (1H) magnetic resonance (MR) spectroscopy with dynamic contrast material-enhanced MR imaging can help differentiate between benign and malignant musculoskeletal tumors. MATERIALS AND METHODS: MR imaging was performed in 36 consecutive patients with bone and soft-tissue tumors larger than 1.5 cm in diameter. Examinations were performed at 1.5 T with a surface coil appropriate for the location of the lesions. Single-voxel 1H MR spectroscopy was performed by using a point-resolved spectroscopic sequence with echo times of 40, 135, and 270 msec. The volume of interest within lesions was positioned on the areas of early enhancement (<8 seconds after arterial enhancement) according to the findings of dynamic contrast-enhanced MR imaging with subtraction. The criterion for determining whether choline was present in a lesion was a clearly identifiable peak at 3.2 ppm in at least two of the three spectra acquired at echo times. MR spectroscopic results and histopathologic findings were determined in blinded fashion and compared with κ statistics. P < .001 was considered to indicate a significant difference. RESULTS: Choline was detected in 18 of 19 patients with malignant tumors and in three of 17 patients with benign lesions. The three benign lesions included one perineurioma, one giant cell tumor, and one abscess. Choline was not detected in 14 patients with benign lesions nor in one patient with a densely ossifying low-grade parosteal osteosarcoma. In vivo 1H MR spectroscopy characterized bone and soft-tissue tumors, resulting in a sensitivity of 95{\%}, specificity of 82{\%}, and accuracy of 89{\%} (P < .001). CONCLUSION: Choline can be reliably detected in large malignant bone and soft-tissue tumors by using a multiecho point-resolved spectroscopic protocol. 1H MR spectroscopy can help differentiate malignant from benign musculoskeletal tumors by revealing the presence or absence of water-soluble choline metabolites.",
author = "Chien-Kuo Wang and Li, {Chun Wei} and Hsieh, {Tsyh Jyi} and Chien, {Sang Hsiung} and Liu, {Gin Chung} and Tsai, {Kun Bow}",
year = "2004",
month = "8",
day = "1",
doi = "10.1148/radiol.2322031441",
language = "English",
volume = "232",
pages = "599--605",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "2",

}

Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy : Initial results. / Wang, Chien-Kuo; Li, Chun Wei; Hsieh, Tsyh Jyi; Chien, Sang Hsiung; Liu, Gin Chung; Tsai, Kun Bow.

In: Radiology, Vol. 232, No. 2, 01.08.2004, p. 599-605.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy

T2 - Initial results

AU - Wang, Chien-Kuo

AU - Li, Chun Wei

AU - Hsieh, Tsyh Jyi

AU - Chien, Sang Hsiung

AU - Liu, Gin Chung

AU - Tsai, Kun Bow

PY - 2004/8/1

Y1 - 2004/8/1

N2 - PURPOSE: To determine if in vivo detection of choline by using hydrogen 1 (1H) magnetic resonance (MR) spectroscopy with dynamic contrast material-enhanced MR imaging can help differentiate between benign and malignant musculoskeletal tumors. MATERIALS AND METHODS: MR imaging was performed in 36 consecutive patients with bone and soft-tissue tumors larger than 1.5 cm in diameter. Examinations were performed at 1.5 T with a surface coil appropriate for the location of the lesions. Single-voxel 1H MR spectroscopy was performed by using a point-resolved spectroscopic sequence with echo times of 40, 135, and 270 msec. The volume of interest within lesions was positioned on the areas of early enhancement (<8 seconds after arterial enhancement) according to the findings of dynamic contrast-enhanced MR imaging with subtraction. The criterion for determining whether choline was present in a lesion was a clearly identifiable peak at 3.2 ppm in at least two of the three spectra acquired at echo times. MR spectroscopic results and histopathologic findings were determined in blinded fashion and compared with κ statistics. P < .001 was considered to indicate a significant difference. RESULTS: Choline was detected in 18 of 19 patients with malignant tumors and in three of 17 patients with benign lesions. The three benign lesions included one perineurioma, one giant cell tumor, and one abscess. Choline was not detected in 14 patients with benign lesions nor in one patient with a densely ossifying low-grade parosteal osteosarcoma. In vivo 1H MR spectroscopy characterized bone and soft-tissue tumors, resulting in a sensitivity of 95%, specificity of 82%, and accuracy of 89% (P < .001). CONCLUSION: Choline can be reliably detected in large malignant bone and soft-tissue tumors by using a multiecho point-resolved spectroscopic protocol. 1H MR spectroscopy can help differentiate malignant from benign musculoskeletal tumors by revealing the presence or absence of water-soluble choline metabolites.

AB - PURPOSE: To determine if in vivo detection of choline by using hydrogen 1 (1H) magnetic resonance (MR) spectroscopy with dynamic contrast material-enhanced MR imaging can help differentiate between benign and malignant musculoskeletal tumors. MATERIALS AND METHODS: MR imaging was performed in 36 consecutive patients with bone and soft-tissue tumors larger than 1.5 cm in diameter. Examinations were performed at 1.5 T with a surface coil appropriate for the location of the lesions. Single-voxel 1H MR spectroscopy was performed by using a point-resolved spectroscopic sequence with echo times of 40, 135, and 270 msec. The volume of interest within lesions was positioned on the areas of early enhancement (<8 seconds after arterial enhancement) according to the findings of dynamic contrast-enhanced MR imaging with subtraction. The criterion for determining whether choline was present in a lesion was a clearly identifiable peak at 3.2 ppm in at least two of the three spectra acquired at echo times. MR spectroscopic results and histopathologic findings were determined in blinded fashion and compared with κ statistics. P < .001 was considered to indicate a significant difference. RESULTS: Choline was detected in 18 of 19 patients with malignant tumors and in three of 17 patients with benign lesions. The three benign lesions included one perineurioma, one giant cell tumor, and one abscess. Choline was not detected in 14 patients with benign lesions nor in one patient with a densely ossifying low-grade parosteal osteosarcoma. In vivo 1H MR spectroscopy characterized bone and soft-tissue tumors, resulting in a sensitivity of 95%, specificity of 82%, and accuracy of 89% (P < .001). CONCLUSION: Choline can be reliably detected in large malignant bone and soft-tissue tumors by using a multiecho point-resolved spectroscopic protocol. 1H MR spectroscopy can help differentiate malignant from benign musculoskeletal tumors by revealing the presence or absence of water-soluble choline metabolites.

UR - http://www.scopus.com/inward/record.url?scp=3242782374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242782374&partnerID=8YFLogxK

U2 - 10.1148/radiol.2322031441

DO - 10.1148/radiol.2322031441

M3 - Article

C2 - 15286325

AN - SCOPUS:3242782374

VL - 232

SP - 599

EP - 605

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 2

ER -